Biological therapy of melanoma

Cover Page

Cite item

Full Text

Abstract

Melanoma is a malignant skin tumor characterized by a high prevalence both in the Russian Federation and around the world, rapid growth, the ability to local and distant metastasis, and high mortality. The discovery and introduction of monoclonal antibodies made it possible to achieve certain successes in the treatment of a number of diseases, including melanoma. High efficiency of using monoclonal antibodies is achieved due to their precisely targeted action on certain molecules, which allowed to increase the overall survival of patients with malignant neoplasms. As a treatment for melanoma, immune control checkpoint inhibitors (CTLA-4 and PD-1), such as ipilimumab, nivolumab, and pembrolizumab, have been shown to be highly effective. The effectiveness of these monoclonal antibodies was confirmed in studies where they were prescribed as monotherapy and combination therapy and was expressed in an increase in the overall survival of patients with skin melanoma. However, monoclonal antibody therapy may be associated with a risk of adverse reactions. The purpose of this review is to generalize current data on the biological treatment of melanoma.

About the authors

Anzhela S. Kravchenko

Russian Medical Academy of Continuous Professional Education

Email: agrevtseva@mail.ru
канд. мед наук, каф. дерматовенерологии и косметологии Москва, Россия

References

  1. Меланома кожи и слизистых оболочек. Клинические рекомендации. 2018.
  2. Garbe С, Peris K, Hauschild A et al. Diagnosis and treatment of melanoma. European consensusbased interdisciplinary guideline - Update 2016. Eur J Cancer 2016; 63: 201-17.
  3. Малишевская Н.П., Соколова А.В., Демидов Л.В. Современное состояние заболеваемости меланомой кожи. Мед. совет. 2018; 10: 161-5.
  4. Кабанова М.А. Эпидемиологическая ситуация по заболеваемости меланомой в России в 2015 году. Современные проблемы здравоохранения и медицинской статистики. 2017; 3: 23-36.
  5. Канева П.Л., Мильчаков Д.Е. Сравнительная характеристика заболеваемости меланомой в некоторых субъектах Приволжского федерального округа. Междунар. научно-исследовательский журн. 2015; 2 (33): 38-9.
  6. Haurum JS. Recombinant polyclonal antibodies: the next generation of antibody therapeutics? Drug Discov Today 2006; 11: 655-60.
  7. McDermott D, Lebbe C, Hodi FS et al. Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. Cancer Treatment Rev 2014; 40 (9): 1056-64.
  8. Beck A, Wurch T, Bailly C, Corvaia N. Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol 2010; 10: 345-52.
  9. Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 2010; 9: 767-74.
  10. Masami S, Chie K, Atsuhiko Kato. Concise Review Therapeutic antibodies: their mechanisms of action and the pathological findings they induce in toxicity studies. J Toxicol Pathol 2015; 28: 133-9.
  11. Foltz IN, Karow M, Wasserman SM. Evolution and Emergence of Therapeutic Monoclonal Antibodies. Circulation 2013; 127: 2222-30.
  12. Daeron M. Fc receptor biology. Annu Rev Immunol 1997; 15: 203-34.
  13. Chiu ML, Goulet DR, Teplyakov A, Gilliland GL. Antibody Structure and Function: The Basis for Engineering Therapeutics. Antibodies (Basel) 2019; 8 (4): 55.
  14. Kolar GR, Capra DJ. Immunoglobulins: structure and function. In: Paul WE, ed. Fundamental Immunology. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2003.
  15. Janda A, Bowen A, Greenspan NS, Casadevall A. Ig Constant Region Effects on Variable Region Structure and Function. Front Microbiol 2016; 7: 1-10.
  16. Keizer RJ, Huitema AD, Schellens JH, Beijnen JH. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 2010; 49: 493-507.
  17. Brunton L, Chabner BA, Knollman B. Goodman and Gilman's The Pharmacological Basis of Therapeutics, Twelfth. McGraw-Hill Education/Medical; 12 edition (16 Feb. 2011).
  18. Katzung B, Masters SB, Trevor AJ. Basic and Clinical Pharmacology, 11th Edition (Lange Basic Science). McGraw-Hill Medical; 11 edition (1 Aug. 2009).
  19. Tang P Liang S, Xu J et al. Screening of Monoclonal Antibodies for Cancer Treatment. J Clin Exp Oncol 2018; 7: 4.
  20. Beckman RA, Weiner LM, Davis HM. Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors. Cancer 2007; 109 (2): 170-9.
  21. Peters S, Stahel RA (eds): Successes and Limitations of Targeted Cancer Therapy. Prog Tumor Res Basel Karger 2014; 41.
  22. Reslan L, Dalle S, Dumontet C. Understanding and circumventing resistance to anticancer monoclonal antibodies. MAbs 2009; 1 (3): 222-9.
  23. Leach DR, Krummel MF, Allison JP Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996; 271 (5256): 1734-6.
  24. Pons-Tostivint E, Latouche A, Vaflard P et al. Comparative analysis of durable responses on immune checkpoint inhibitors versus other systemic therapies: a pooled analysis of phase III trials. JCO Precis Oncol 2019; 3: 1-10.
  25. Hodi FS, O‘Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363 (8): 711-23.
  26. Sharpe AH. Mechanisms of costimulation. Immunol Rev 2009; 229 (1): 5-11.
  27. Egen JG, Allison JP. Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength. Immunity 2002; 16 (1): 23-35.
  28. Du X, Tang F, Liu M et al. A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy. Cell Res 2018; 28 (4): 416-32.
  29. Simon S, Labarriere N. PD-1 expression on tumor-specific T cells: friend or foe for immunotherapy? Oncoimmunology 2017; 7 (1): e1364828-e1364828.
  30. Kil SH, Estephan R, Sanchez J et al. PD-L1 is regulated by interferon gamma and interleukin 6 through STAT1 and STAT3 signaling in cutaneous T-cell lymphoma. Blood 2017; 130 (Suppl. 1): 1458.
  31. Przepiorka D, Ko CW, Deisseroth A et al. FDA approval: blinatumomab. Clin Cancer Res 2015; 21 (18): 4035-9.
  32. Wan MT, Ming ME. Nivolumab versus ipilimumab in the treatment of advanced melanoma: a critical appraisal. Br J Dermatol 2018; 179 (2): 296-300.
  33. Rogiers A, Boekhout A, Schwarze JK et al. Long-Term Survival, Quality of Life, and Psychosocial Outcomes in Advanced Melanoma Patients Treated with Immune Checkpoint Inhibitors. J Oncol 2019: 5269062.
  34. Amaral T, Seeber O, Mersi E et al. Primary Resistance to PD-1-Based Immunotherapy - A Study in 319 Patients with Stage IV Melanoma. Cancers 2020; 12 (4): 1027.
  35. Brahmer JR, Drake CG, Wollner I et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010; 28 (19): 3167-75.
  36. Schadendorf D, Hodi FS, Robert C et al. Pooled Analysis of Long-Term Survival Data from Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol 2015; 33 (17): 1889-94.
  37. Robert C, Schachter J, Long GV et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med 2015; 372 (26): 2521-32.
  38. Robert C, Long GV, Brady B et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372 (4): 320-30.
  39. Hodi FS, Chiarion-Sileni V, Gonzalez R et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol 2018; 19: 1480-92.
  40. Larkin J, Chiarion-Sileni V, Gonzalez R et al. Abstract CT075: Overall survival (OS) results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naive patients with advanced melanoma (CheckMate 067). Cancer Res 2017; 77 (Suppl. 13): CT075.
  41. Long GV, Atkinson V, Menzies AM et al. A randomized phase II study of nivolumab or nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases (mets): The Anti-PD1 Brain Collaboration (ABC). 2017; Abstract 9508.

Copyright (c) 2020 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies